HTGF backs MYR GmbH

The fresh capital will enable the company to start phase 1 of its clinical development in summer 2011, having successfully completed pre-clinical studies.

Company
Founded in 2010, MYR GmbH is located in Burgwedel near Hannover. The company develops the viral entry inhibitor Myrcludex for the treatment of chronic hepatitis B and D infections. MYR currently has two employees, who are focused on the coordination of the network of academic partners and vendors involved in the Myrcludex development.

People
Dr Bernd Goergen, senior investment manager, handled the investment for High-Tech Gründerfonds.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Now researching
• Healthcare
• DACH
• Early-stage
• High-Tech Gründerfonds